Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | AR | P10275 | 1/20 | 0.44 |
| ▸ | ATM | Q13315 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | CYP24A1 | Q07973 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.43 |
| ▸ | BCHE | P06276 | 1/20 | 0.43 |
| ▸ | ACHE | P22303 | 1/20 | 0.43 |
| ▸ | CA12 | O43570 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CA9 | Q16790 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.42 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | PIR | O00625 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25206305 | 0.99 | ALDH1A1 (0.48) | ALDH1A1GAAPKMLMNAAR | |
| SCHEMBL26979071 | 0.99 | ALDH1A1 (0.48) | ALDH1A1GAAPKMLMNAAR | |
| SCHEMBL2241875 | 0.99 | ALDH1A1 (0.48) | ALDH1A1GAAPKMLMNAAR | |
| SCHEMBL29172709 | 0.99 | ALDH1A1 (0.48) | ALDH1A1GAAPKMLMNAAR | |
| SCHEMBL9872166 | 0.99 | ALDH1A1 (0.48) | ALDH1A1GAAPKMLMNAAR | |
| SCHEMBL2246161 | 0.97 | ALDH1A1 (0.49) | ALDH1A1GAAPKMLMNAAR | |
| SCHEMBL18428703 | 0.96 | ALDH1A1 (0.47) | ALDH1A1GAAPKMLMNAAR | |
| SCHEMBL25311278 | 0.96 | ALDH1A1 (0.48) | ALDH1A1GAAPKMLMNAAR | |
| SCHEMBL23250068 | 0.94 | ALDH1A1 (0.47) | ALDH1A1GAAPKMLMNAAR | |
| SCHEMBL21405231 | 0.94 | ALDH1A1 (0.47) | ALDH1A1GAAPKMLMNAAR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260115296-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF RAPIDLY ACCELERATED FIBROSARCOMA POLYPEPTIDES | UNIV YALE (US) | 2026-04-30 | — | — | US | disclosed |
| US-11986531-B2 | Compounds and methods for the targeted degradation of rapidly accelerated fibrosarcoma polypeptides | ARVINAS OPERATIONS, INC. (US) | 2024-05-21 | — | — | US | disclosed |
| US-11964945-B2 | Compounds and methods for the targeted degradation of androgen receptor | ARVINAS OPERATIONS, INC. (US) | 2024-04-23 | — | — | US | disclosed |
| US-11952347-B2 | Compounds and methods for the targeted degradation of androgen receptor | ARVINAS OPERATIONS, INC. (US) | 2024-04-09 | — | — | US | disclosed |
| WO-2024054954-A1 | HETEROBIFUNCTIONAL COMPOUNDS AND METHODS OF TREATING DISEASE | HALDA THERAPEUTICS OPCO, INC. (US) | 2024-03-14 | — | — | WO | disclosed |
| US-20240059686-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF THE ANDROGEN RECEPTOR | ARVINAS OPERATIONS, INC. (US) | 2024-02-22 | — | — | US | disclosed |
| CN-117510491-A | Compounds and methods for rapid accelerated targeted degradation of fibrosarcoma polypeptides | 阿尔维纳斯运营股份有限公司 | 2024-02-06 | — | — | CN | disclosed |
| EP-3512842-B1 | INDOLE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS | ARVINAS INC (US) | 2024-01-17 | — | — | EP | disclosed |
| US-20230357134-A1 | AGENTS FOR USE IN THE TREATMENT OF AMYLOIDOSIS | UCL BUSINESS LTD (GB) | 2023-11-09 | — | — | US | disclosed |
| US-20230331681-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | ARVINAS OPERATIONS, INC. | 2023-10-19 | — | — | US | disclosed |
| US-20180179183-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF RAPIDLY ACCELERATED FIBROSARCOMA POLYPEPTIDES | ARVINAS OPERATIONS, INC. | 2018-06-28 | — | — | US | disclosed |
| US-20180099940-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | ARVINAS OPERATIONS, INC. | 2018-04-12 | — | — | US | disclosed |
| WO-2018053354-A1 | INDOLE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS | Arvinas, Inc. (US) | 2018-03-22 | — | — | WO | disclosed |
| US-20180072711-A1 | INDOLE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS | ARVINAS OPERATIONS, INC. | 2018-03-15 | — | — | US | disclosed |
| CN-107428734-A | Compounds and methods for targeted degradation of androgen receptors | 阿尔维纳斯股份有限公司 | 2017-12-01 | — | — | CN | disclosed |
| US-20170327469-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | ARVINAS OPERATIONS, INC. | 2017-11-16 | — | — | US | disclosed |
| US-20160214972-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | ARVINAS OPERATIONS, INC. | 2016-07-28 | — | — | US | disclosed |
| US-5070139-A | PLATELET ACTIVATING FACTOR ANTAGONISTS, HYPOTENSIVES | J. URIACH & CIA. S.A. (ES) | 1991-12-03 | — | — | US | disclosed |
| US-4940706-A | 2,4-disubstituted 1,3-dioxolanes and pharmaceutical use | J. URIACH & CIA, S.A. (ES) | 1990-07-10 | — | — | US | disclosed |
| EP-0312041-A2 | 2,4-Disubstituted 1,3-dioxolanes | J. URIACH & CIA. S.A. (ES) | 1989-04-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180179183-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF RAPIDLY ACCELERATED FIBROSARCOMA POLYPEPTIDES | CRBN, ARAF, VHL | ALDH1A1 2833/4885GAA 1531/4885PKM 3978/4885 |
| US-20160214972-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | AR, ESRRA, MDM2 | ALDH1A1 460/4885GAA 1291/4885PKM 2985/4885 |
| US-20230331681-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | AR, ADRM1, CRBN | ALDH1A1 798/4885GAA 1082/4885PKM 3679/4885 |
| US-20180072711-A1 | INDOLE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS | ESR1, GPER1, ESR2 | ALDH1A1 1117/4885GAA 1316/4885PKM 2365/4885 |
| US-20170327469-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | AR, MDM2, ESRRA | ALDH1A1 514/4885GAA 1071/4885PKM 2962/4885 |
| US-20180099940-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | AR, ADRM1, CRBN | ALDH1A1 824/4885GAA 1094/4885PKM 3709/4885 |
| US-20240059686-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF THE ANDROGEN RECEPTOR | AR, VHL, MDM2 | ALDH1A1 520/4885GAA 1379/4885PKM 2959/4885 |
| US-11964945-B2 | Compounds and methods for the targeted degradation of androgen receptor | AR, ADRM1, CRBN | ALDH1A1 824/4885GAA 1094/4885PKM 3709/4885 |
| US-11952347-B2 | Compounds and methods for the targeted degradation of androgen receptor | AR, ADRM1, CRBN | ALDH1A1 798/4885GAA 1082/4885PKM 3679/4885 |
| US-20230357134-A1 | AGENTS FOR USE IN THE TREATMENT OF AMYLOIDOSIS | TTR, C1R, APOB | ALDH1A1 1891/4885GAA 202/4885PKM 3379/4885 |
| US-11986531-B2 | Compounds and methods for the targeted degradation of rapidly accelerated fibrosarcoma polypeptides | CRBN, ARAF, VHL | ALDH1A1 2833/4885GAA 1531/4885PKM 3978/4885 |
| US-20260115296-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF RAPIDLY ACCELERATED FIBROSARCOMA POLYPEPTIDES | CRBN, VHL, ADRM1 | ALDH1A1 2777/4885GAA 2139/4885PKM 3637/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.